瑞帕妥单抗治疗成人难治性肾病综合征的疗效及安全性分析
Efficacy and Safety Analysis of Ripertamab in the Treatment of Refractory Nephrotic Syndrome in Adults
DOI: 10.12677/jcpm.2025.42182, PDF,    科研立项经费支持
作者: 呼思乐, 程 月：包头医学院研究生院，内蒙古 包头；吕 丽, 李增艳*：包头医学院第一附属医院肾内科，内蒙古 包头
关键词: 难治性肾病综合征；CD20单抗；瑞帕妥单抗；综合性治疗；Refractory Nephrotic Syndrome； CD20 Monoclonal Antibody； Ripertamab； Comprehensive Treatment
摘要: 难治性肾病综合征(refractory nephropathy syndrome, RNS)是一种复杂的临床综合征，患者通常对激素和免疫抑制剂治疗反应不佳，面临频繁复发的风险。CD20单抗通过靶向B细胞表面抗原，调节免疫反应，已被证明在改善RNS患者的临床症状和生化指标方面具有良好的疗效。CD20单抗分为三代，包括以利妥昔单抗为代表的第一代、以奥法木单抗为代表的第二代和以瑞帕妥单抗为代表的第三代。这些单抗通过耗竭CD20+ B淋巴细胞，减少蛋白尿，发挥治疗作用。本文通过阐述CD20单抗的分类、作用机制和瑞帕妥单抗的优势；同时分析不同代CD20单抗在RNS中的应用及其疗效和安全性，旨在对CD20单抗治疗RNS的研究进展作一综述。
Abstract: Refractory nephropathy syndrome (RNS) is a complex clinical syndrome in which patients often do not respond well to hormone and immunosuppressive therapy and are at risk of frequent recurrence. CD20 monoclonal antibodies, by targeting B cell surface antigens, regulate the immune response and have been shown to be effective in improving clinical symptoms and biochemical indicators in patients with RNS. CD20 monoclonal antibodies are divided into three generations: the first generation, represented by rituximab; the second generation, represented by ofatumumab; and the third generation, represented by ripertamab. These monoclonal antibodies exert their therapeutic effects by depleting CD20+ B lymphocytes and reducing proteinuria. This review describes the classification of CD20 monoclonal antibodies, their mechanisms of action, and the advantages of ripertamab. It also analyzes the application, efficacy, and safety of different generations of CD20 monoclonal antibodies in RNS, aiming to provide an overview of the research progress in the treatment of RNS with CD20 monoclonal antibodies.
文章引用：呼思乐, 吕丽, 程月, 李增艳. 瑞帕妥单抗治疗成人难治性肾病综合征的疗效及安全性分析[J]. 临床个性化医学, 2025, 4(2): 339-348. https://doi.org/10.12677/jcpm.2025.42182

参考文献

[1] Chan, E.Y., Yap, D.Y., Colucci, M., Ma, A.L., Parekh, R.S. and Tullus, K. (2023) Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology, 18, 533-548. [Google Scholar] [CrossRef] [PubMed]
[2] 闫星域, 夏运风. 过敏性紫癜性肾炎的治疗进展[J]. 医学综述, 2020, 26(20): 4088-4092.
[3] Webb, N.J.A., Woolley, R.L., Lambe, T., Frew, E., Brettell, E.A., Barsoum, E.N., et al. (2019) Long Term Tapering versus Standard Prednisolone Treatment for First Episode of Childhood Nephrotic Syndrome: Phase III Randomised Controlled Trial and Economic Evaluation. BMJ, 365, l1800. [Google Scholar] [CrossRef] [PubMed]
[4] Ravani, P., Rossi, R., Bonanni, A., Quinn, R.R., Sica, F., Bodria, M., et al. (2015) Rituximab in Children with Steroid-Dependent Nephrotic Syndrome. A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. Journal of the American Society of Nephrology, 26, 2259-2266. [Google Scholar] [CrossRef] [PubMed]
[5] Trautmann, A., Vivarelli, M., Samuel, S., Gipson, D., Sinha, A., Schaefer, F., et al. (2020) IPNA Clinical Practice Recommendations for the Diagnosis and Management of Children with Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 35, 1529-1561. [Google Scholar] [CrossRef] [PubMed]
[6] Iijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., et al. (2014) Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 384, 1273-1281. [Google Scholar] [CrossRef] [PubMed]
[7] 周巧玲, 唐荣. 如何应对难治性肾病综合征[J]. 肾脏病与透析肾移植杂志, 2019, 28(2): 145-146.
[8] 阮一平, 洪富源. 膜性肾病免疫抑制治疗的进展[J]. 内科急危重症杂志, 2019, 25(4): 277-280.
[9] Geh, D. and Gordon, C. (2018) Epratuzumab for the Treatment of Systemic Lupus Erythematosus. Expert Review of Clinical Immunology, 14, 245-258. [Google Scholar] [CrossRef] [PubMed]
[10] Furman, R.R., Coleman, M. and Leonard, J.P. (2004) Epratuzumab in Non-Hodgkin’ Lymphomas. Current Treatment Options in Oncology, 5, 283-288. [Google Scholar] [CrossRef] [PubMed]
[11] Franca, R., Favretto, D., Granzotto, M., Decorti, G., Rabusin, M. and Stocco, G. (2017) Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives. Current Medicinal Chemistry, 24, 1050-1065. [Google Scholar] [CrossRef] [PubMed]
[12] 刘嘉榆, 黄方, 郝思国. 慢性粒-单核细胞白血病合并免疫性血小板减少症1例[J]. 上海交通大学学报(医学版), 2024, 44(2): 287-290.
[13] 王健, 马林楠. 利妥昔单抗用于初诊CD20阳性B-ALL患儿的效果及预后分析[J]. 检验医学与临床, 2023, 20(12): 1716-1720.
[14] Santos, J.E., Fiel, D., Santos, R., Vicente, R., Aguiar, R., Santos, I., et al. (2020) Rituximab Use in Adult Glomerulopathies and Its Rationale. Brazilian Journal of Nephrology, 42, 77-93. [Google Scholar] [CrossRef] [PubMed]
[15] 蓝清华, 曾庆芳, 宋欢, 等. CD20单抗联合苯达莫司汀治疗惰性淋巴瘤的疗效及安全性[J]. 癌症进展, 2023, 21(12): 1302-1305.
[16] 张婕, 何伟春. 抗CD20单克隆抗体治疗特发性膜性肾病的研究进展[J]. 中国医药, 2021, 16(7): 1104-1107.
[17] 杨佳, 高洁, 赵文静, 徐强, 李海英, 于晨, 董华. 泰它西普在IgA肾病和狼疮性肾炎中的研究进展[J]. 中国现代医学杂志, 2022, 32(19):51-56.
[18] 刘中天, 张嘉静, 林涛发, 等. 通过CD20单抗打破小鼠HBV免疫耐受研究Bregs细胞在慢性乙型肝炎中的作用[J]. 肝脏, 2023, 28(10): 1212-1214+1218.
[19] 管娜, 丁洁. 抗CD20单克隆抗体治疗难治性肾病综合征[J]. 儿科药学杂志, 2010, 16(5): 1-3.
[20] 孙蕊, 朱琰, 冯海凉, 等. 抗CD20单克隆抗体治疗B细胞淋巴瘤的效应机制[J]. 现代生物医学进展, 2016, 16(5): 950-955.
[21] 季垠宏, 任红. 利妥昔单抗治疗局灶节段性肾小球硬化症机制的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(5): 693-697.
[22] 范耀冰, 李艳艳, 吴红赤. 特发性膜性肾病免疫抑制治疗的最新进展[J]. 临床与病理杂志, 2021, 41(7): 1703-1708.
[23] 谭虹. 利妥昔单抗治疗难治性肾病综合征的疗效分析[J]. 中华养生保健, 2023, 41(2): 175-178.
[24] 任相阁, 禹欣, 张佳伟, 等. 真实世界中利妥昔单抗治疗儿童难治性肾病综合征的有效性与安全性的Meta分析[J]. 中国药房, 2024, 35(21): 2668-2675.
[25] 朱冰冰, 袁婷婷, 李艳. 利妥昔单抗与环磷酰胺联合醋酸泼尼松治疗儿童难治性肾病综合征的效果比较[J]. 中国民康医学, 2024, 36(11): 139-141+145.
[26] 黄敏, 王晓霞, 王晓春, 等. 极低剂量利妥昔单抗治疗原发性难治性肾病综合征的疗效及对肾功能、免疫球蛋白、Toll样受体的影响[J]. 临床肾脏病杂志, 2022, 22(10): 827-833.
[27] 朱剑红. 环磷酰胺联合利妥昔单抗注射液治疗儿童难治性肾病综合征的临床疗效及其对肾功能、免疫功能的影响[J]. 临床合理用药杂志, 2022, 15(6): 159-161.
[28] Li, K., Yu, Y.Q., Gao, Y., Zhao, F., Liang, Z. and Gao, J.J. (2022) Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis. Frontiers in Immunology, 13, Article 859380. [Google Scholar] [CrossRef] [PubMed]
[29] Zhou, J., Tao, M.-J., Jin, L.-R., Sheng, J., Li, Z., Peng, H., et al. (2019) Effectiveness and Safety of Common Therapeutic Drugs for Refractory Lupus Nephritis: A Network Meta-Analysis. Experimental and Therapeutic Medicine, 19, 665-671. [Google Scholar] [CrossRef] [PubMed]
[30] Dai, P.Y., Xie, W.H., Yu, X.J., Sun, J.F., Wang, S.Y. and Kawuki, J. (2021) Efficacy and Cost of Different Treatment in Patients with Idiopathic Membranous Nephropathy: A Network Meta-Analysis and Cost-Effectiveness Analysis. International Immunopharmacology, 94, Article 107376. [Google Scholar] [CrossRef] [PubMed]
[31] 周燚, 王梦婷, 褚睿, 陈孟华. 特发性膜性肾病发病机制研究进展[J]. 宁夏医科大学学报, 2019, 41(8): 860-864.
[32] 伍敏, 魏青, 刘必成. 原发性膜性肾病诊断及治疗新进展[J]. 中国实用内科杂志, 2023, 43(3): 183-187.
[33] 李岩, 闫雨婷, 陈佳, 等. 奥妥珠单抗相关不良反应的防治研究[J]. 中国医院用药评价与分析, 2024, 24(7): 893-896.
[34] 药品资讯网. 依鲁替尼联合奥法木单抗疗法治疗CLL患者安全有效[J]. 临床合理用药杂志, 2015, 8(26): 22.
[35] 于力. 生物制剂在儿童肾病综合征中的应用[J]. 实用医学杂志, 2021, 37(15): 1911-1915.
[36] 张锐, 陶永丽, 蒋晨阳, 等. 奥法妥木单抗治疗视神经脊髓炎谱系疾病疗效分析[J]. 中国现代神经疾病杂志, 2024, 24(6): 491-496.
[37] 李莹, 关茗元, 段冉冉, 等. 基于FAERS数据库对奥法妥木单抗及利妥昔单抗治疗多发性硬化的不良事件分析[J]. 中国药学杂志, 2024, 59(9): 845-851.
[38] 白立娜, 周健楠. 奥妥珠单抗治疗难治性肾病综合征不良反应的预防与管理实践[J]. 中国现代医药杂志, 2024, 26(9): 98-100.
[39] 李刚, 李洛华. 奥妥珠单抗治疗利妥昔单抗耐药膜性肾病的临床疗效分析[J]. 中国现代医生, 2024, 62(32): 87-90.
[40] Bondza, S., Marosan, A., Kara, S., Lösing, J., Peipp, M., Nimmerjahn, F., et al. (2021) Complement-Dependent Activity of CD20-Specific IgG Correlates with Bivalent Antigen Binding and C1q Binding Strength. Frontiers in Immunology, 11, Article 609941. [Google Scholar] [CrossRef] [PubMed]
[41] Evers, M., Rösner, T., Dünkel, A., Jansen, J.H.M., Baumann, N., ten Broeke, T., et al. (2021) The Selection of Variable Regions Affects Effector Mechanisms of IgA Antibodies against CD20. Blood Advances, 5, 3807-3820. [Google Scholar] [CrossRef] [PubMed]
[42] Bondza, S., ten Broeke, T., Nestor, M., Leusen, J.H.W. and Buijs, J. (2020) Bivalent Binding on Cells Varies between Anti-CD20 Antibodies and Is Dose-Dependent. MABS, 12, e1792673. [Google Scholar] [CrossRef] [PubMed]
[43] Roccatello, D., Sciascia, S., Rossi, D., Solfietti, L., Fenoglio, R., Menegatti, E., et al. (2017) The Challenge of Treating Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis in the Era of Anti-CD20 Monoclonal Antibodies and Direct Antiviral Agents. Oncotarget, 8, 41764-41777. [Google Scholar] [CrossRef] [PubMed]
[44] Leandro, M. and Isenberg, D.A. (2021) Rituximab—The First Twenty Years. Lupus, 30, 371-377. [Google Scholar] [CrossRef] [PubMed]
[45] Alalawi, M., Bakr, A.S., Reda, R., Sadak, K.T. and Nagy, M. (2022) Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients. Immunotherapy, 14, 1067-1083. [Google Scholar] [CrossRef] [PubMed]
[46] 陈思洁, 王凤梅, 张晓良, 刘必成, 汤日宁. 新型免疫抑制剂在狼疮肾炎治疗中的进展[J]. 中华肾脏病杂志, 2021, 37(11): 937-944.